Patients with insulin-dependent diabetes or coronary heart disease following rehabilitation express serum fractalkine levels similar to those in healthy control subjects.
The chemokine and adhesion molecule fractalkine and its receptor CX(3)CR1 have emerged as interesting regulators in inflammation and related atherosclerosis. The pro-inflammatory status may be counteracted by appropriate treatment, such as in rehabilitation. We compared serum fractalkine concentrations of 46 patients with coronary heart disease (CHD) and 47 insulin-dependent diabetic patients (IDDM) following rehabilitation with those of 50 control subjects. Following rehabilitation serum fractalkine levels (477 + or - 225 pg/mL) in CHD patients were similar to those in control subjects (572 + or - 205 pg/mL; P = 0.303), whereas fractalkine levels were lower in IDDM patients (430 + or - 256 pg/mL; P = 0.042). No significant difference between CHD and IDDM patients was present (P = 0.319). Postprandial hyperlipemia may influence inflammation; thus, we investigated fractalkine levels four and eight hours after inducing postprandial hyperlipemia. However, we did not find any significant alterations in CHD and diabetic patients, whereas the fractalkine levels in controls were reduced. In vitro, lipofundin used as a hyperlipemic stimulus was added to vessel wall cells and reduced fractalkine levels. Low fractalkine levels in patients attending rehabilitation indicate a beneficial effect of the rehabilitation procedure on innate inflammatory pathways, such as the chemokine and adhesion molecule fractalkine.
Universitätsklinik und Poliklinik für Innere Medizin III, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany. maegdefessel@stanford.edu
Lars
L
Maegdefessel
Axel
A
Schlitt
Susanna
S
Pippig
Bernhard
B
Schwaab
Kerstin
K
Fingscheidt
Uwe
U
Raaz
Michael
M
Buerke
Harald
H
Loppnow
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D002478:Cells, Cultured; D054428:Chemokine CX3CL1 / Q000097:blood*; D003327:Coronary Disease / Q000276:immunology* / Q000534:rehabilitation; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000534:rehabilitation; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000276:immunology; D018836:Inflammation Mediators / Q000097:blood*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000276:immunology; D032389:Myocytes, Smooth Muscle / Q000276:immunology; D019518:Postprandial Period / Q000276:immunology; D016896:Treatment Outcome
D015415:Biomarkers; C515538:CX3CL1 protein, human; D054428:Chemokine CX3CL1; D018836:Inflammation Mediators; D008055:Lipids; D002097:C-Reactive Protein